Regulated information

Sales 3rd quarter 2023: 136M€

The Vetoquinol Group posted sales of €136 million in Q3 2023, up +1.3% on a reported basis and +5.1% at constant exchange rates. Over the same period, Vetoquinol recorded a negative currency impact of -€5 million, linked to the Americas and Asia Pacific/Rest of World territories.

Annual sales 2022

Total group Sales: €540 million (up 3.6% as reported)
Annual Sales of Essential products: €304 million (up 4.5% as reported)

Q1 2023 Sales: €145M

Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates.

Q1 2020 sales €103.4 million (Up 13.7%)

Vetoquinol Group sales for Q1 2020 amounted to €103.4 million, up 13.7% as reported and up 13.4% at constant exchange rates.

Q3 2020 sales: €114.5 million* (Up 14.3%)

Vetoquinol posted sales of €114.5 million for the third quarter of 2020, up 14.3% as reported compared to the same period last year.

2019 sales: €396.0 million (Up 7.6%)

The Vetoquinol Group posted 2019 sales of €396.0 million, up 7.6% as reported and up 6.1% at constant exchange rates.

2019 annual results: group sales €396.0M, up 6.1% at constant exchange rates. Net income group share: €28.6M (7.2% of sales)

At its meeting on March 24, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2019 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon.

Q3 2014 sales up 11.0%

The Vétoquinol Group reported Q3 2014 sales of €82.2 million, up 11.0% compared to the same period last year (up 11.1% at constant exchange rates).

2020 first half results consolidated sales: €196.1m (up 7.5% at constant exchange rates) net income group share: €15.1m (7.7% of sales)

At its meeting on July 29, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the first half 2020 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon.

Vétoquinol and Bioniche Life Sciences Inc. close sale of Bioniche Animal Health business

Lure, France and Belleville, Ontario, Canada, April 16, 2014 - Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced the closing of the sale of Bioniche’s Animal Health business to Vétoquinol. The two companies announced the signing of a share purchase agreement in February that was subject to the approval of Bioniche shareholders. At a Special Meeting of Shareholders held yesterday, 97.4% of the Shares that were voted were in favour of the transaction.